Amarin - The Science Of Lipid Therapy (Seite 33)
eröffnet am 03.01.14 20:10:32 von
neuester Beitrag 04.04.24 15:47:54 von
neuester Beitrag 04.04.24 15:47:54 von
Beiträge: 1.840
ID: 1.190.027
ID: 1.190.027
Aufrufe heute: 2
Gesamt: 156.339
Gesamt: 156.339
Aktive User: 0
ISIN: US0231112063 · WKN: A0NBNG · Symbol: EH3A
0,9186
USD
-4,01 %
-0,0384 USD
Letzter Kurs 02:00:00 Nasdaq
Neuigkeiten
15.04.24 · globenewswire  |
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 08.04.24 · globenewswire |
06.04.24 · globenewswire |
03.04.24 · globenewswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,0400 | +48,57 | |
| 0,5400 | +38,46 | |
| 31,00 | +24,00 | |
| 21,440 | +23,56 | |
| 0,7900 | +21,54 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,4500 | -20,98 | |
| 0,7350 | -31,31 | |
| 28,18 | -32,62 | |
| 0,5660 | -40,42 | |
| 2,8100 | -48,72 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 66.607.814 von Magnetfeldfredy am 26.01.21 09:14:19
Vorgeschlagener Zeitplan :
Juli 2021- Mai 2022
Zitat von Magnetfeldfredy: Super Meldung, Amarin verklagt nun auch die Krankenversicherungen die zu Unrecht auf generisches Vascepa umswitchen, bravo:
Amarin Expands Cardiovascular Risk Reduction Patent Infringement Lawsuit to Include Health Care Insurance Provider
Amarin Corporation plc
Tue, January 26, 2021, 1:35 AM
Vorgeschlagener Zeitplan :
Juli 2021- Mai 2022
Antwort auf Beitrag Nr.: 67.918.853 von dpdwvz am 22.04.21 21:00:03Der Depp vom Dienst ist auch wieder aufgewacht, abwarten Amarin wird noch wie Phönix aus der Asche auferstehen 😇
....die Fischbonbons haben ja ne mega Performance hingelegt 🤣...beste Grüße an meinen lieben MagnetHorst 😎👍
Zulassung von Vazkepa für Großbritannien und Norwegen
, was macht der Kurs, 1-2 % absolut lächerlich, hoffentlich krepieren die shorties bald:
Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and Healthcare Products Regulatory Agency (MHRA) 1,2
Amarin Corporation plc
Thu, April 22, 2021, 4:53 PM
VAZKEPA (icosapent ethyl) is the first and only authorized treatment for its cardiovascular risk reduction indication1,2,3
VAZKEPA authorization for Great Britain follows recent VAZKEPA authorization for European Union
DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a Marketing Authorization for VAZKEPA (icosapent ethyl) as a treatment to reduce the risk of cardiovascular events in high cardiovascular risk statin-treated adult patients who have elevated triglycerides (≥150 mg/dL) and either established cardiovascular disease or diabetes, and at least one additional cardiovascular risk factor. The Great Britain Marketing Authorization for VAZKEPA applies to England, Scotland and Wales. Under the Brexit Northern Ireland agreement, the European centralized marketing authorization for the European Union covers Northern Ireland.
The MHRA’s license swiftly followed the European Commission (EC) marketing authorization of icosapent ethyl for the European Union as announced on March 30, 2021.3 Amarin’s understanding is that icosapent ethyl is among the first products to be submitted and licensed through the MHRA’s new ‘reliance’ route following the end of the Brexit transition period. Icosapent ethyl has been identified as a new active substance with likely multi-factorial mechanisms of action.1
The MHRA authorization for VAZKEPA is based on over a decade of development and testing of icosapent ethyl, including efficacy and safety data from the REDUCE-IT® cardiovascular outcomes study.2 REDUCE-IT evaluated more than 8,000 high-risk patients who despite having their cholesterol levels well controlled by statin therapy remained at significant risk of heart attack, stroke, or other major adverse cardiovascular events (MACE), including death. As published, patients in the REDUCE-IT study had a median follow-up period of nearly five years. Results from this study, in which all patients remained treated with statins (and with other contemporary therapies) and where half the patients received icosapent ethyl and the other half received placebo, demonstrated a 25% relative risk reduction (p<0.001) in the first occurrence of MACE in the intent-to-treat patient population with use of icosapent ethyl (4 grams daily) compared with placebo.
Professor Gabriel Steg, M.D., Chief, Department of Cardiology at Hôpital Bichat, Paris, commented, “The REDUCE-IT study shows icosapent ethyl could reduce CV events and has the potential to change the way residual cardiovascular risk is treated. This authorization of icosapent ethyl can make a difference to patients who are at high-risk of suffering from a heart attack or stroke. Eligible patients can be confident we have a new treatment that is backed by evidence-based data and European guideline recommendations.”
The publication of this research has led to icosapent ethyl being recommended for use in high-risk statin-treated patients identified by moderately elevated triglycerides by 15 global medical societies around the world including the European Society of Cardiology and the European Atherosclerosis Society.4
Cardiovascular risk (CVD) is one of the leading causes of death in the United Kingdom, with heart and circulatory diseases causing more than a quarter (27%) of all deaths in the UK, which is more than 160,000 deaths each year.5
The marketing authorization is also timely in the wake of the COVID-19 pandemic, which has resulted in the reprioritization of clinical resources, often leaving patients with serious cardiovascular disease to delay much needed medical help.6 Preventative care is needed for at-risk patients with cardiovascular disease, including LDL-cholesterol management and additional treatments for statin-treated patients with residual cardiovascular risk, identified by elevated triglycerides and other risk factors, to address their unmet need.
“Icosapent ethyl has been helping to reduce strokes, heart attacks and other major cardiovascular events in high-risk patients in the United States,” stated John Thero, president and chief executive officer of Amarin. “We are dedicated to the rethinking of cardiovascular disease risk reduction across Europe with an emphasis on preventative care. Amarin will work tirelessly throughout Europe to make icosapent ethyl available to all patients who may benefit from this important therapy.”
In addition, the company announced that subsequent to the marketing authorization by the EC, the Norwegian Medicines Agency informed Amarin of its marketing authorization for VAZKEPA in Norway.
Information regarding Amarin’s plans for commercialization and securing market access in Europe and the United Kingdom can be found in the FAQ section under investor relations at www.amarincorp.com.
About Amarin
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our scientific research foundation to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, and Zug in Switzerland as well as commercial partners and suppliers around the world. We are committed to rethinking cardiovascular risk through the advancement of scientific understanding of the impact on society of significant residual risk that exists beyond traditional therapies, such as statins for cholesterol management.
, was macht der Kurs, 1-2 % absolut lächerlich, hoffentlich krepieren die shorties bald:Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and Healthcare Products Regulatory Agency (MHRA) 1,2
Amarin Corporation plc
Thu, April 22, 2021, 4:53 PM
VAZKEPA (icosapent ethyl) is the first and only authorized treatment for its cardiovascular risk reduction indication1,2,3
VAZKEPA authorization for Great Britain follows recent VAZKEPA authorization for European Union
DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a Marketing Authorization for VAZKEPA (icosapent ethyl) as a treatment to reduce the risk of cardiovascular events in high cardiovascular risk statin-treated adult patients who have elevated triglycerides (≥150 mg/dL) and either established cardiovascular disease or diabetes, and at least one additional cardiovascular risk factor. The Great Britain Marketing Authorization for VAZKEPA applies to England, Scotland and Wales. Under the Brexit Northern Ireland agreement, the European centralized marketing authorization for the European Union covers Northern Ireland.
The MHRA’s license swiftly followed the European Commission (EC) marketing authorization of icosapent ethyl for the European Union as announced on March 30, 2021.3 Amarin’s understanding is that icosapent ethyl is among the first products to be submitted and licensed through the MHRA’s new ‘reliance’ route following the end of the Brexit transition period. Icosapent ethyl has been identified as a new active substance with likely multi-factorial mechanisms of action.1
The MHRA authorization for VAZKEPA is based on over a decade of development and testing of icosapent ethyl, including efficacy and safety data from the REDUCE-IT® cardiovascular outcomes study.2 REDUCE-IT evaluated more than 8,000 high-risk patients who despite having their cholesterol levels well controlled by statin therapy remained at significant risk of heart attack, stroke, or other major adverse cardiovascular events (MACE), including death. As published, patients in the REDUCE-IT study had a median follow-up period of nearly five years. Results from this study, in which all patients remained treated with statins (and with other contemporary therapies) and where half the patients received icosapent ethyl and the other half received placebo, demonstrated a 25% relative risk reduction (p<0.001) in the first occurrence of MACE in the intent-to-treat patient population with use of icosapent ethyl (4 grams daily) compared with placebo.
Professor Gabriel Steg, M.D., Chief, Department of Cardiology at Hôpital Bichat, Paris, commented, “The REDUCE-IT study shows icosapent ethyl could reduce CV events and has the potential to change the way residual cardiovascular risk is treated. This authorization of icosapent ethyl can make a difference to patients who are at high-risk of suffering from a heart attack or stroke. Eligible patients can be confident we have a new treatment that is backed by evidence-based data and European guideline recommendations.”
The publication of this research has led to icosapent ethyl being recommended for use in high-risk statin-treated patients identified by moderately elevated triglycerides by 15 global medical societies around the world including the European Society of Cardiology and the European Atherosclerosis Society.4
Cardiovascular risk (CVD) is one of the leading causes of death in the United Kingdom, with heart and circulatory diseases causing more than a quarter (27%) of all deaths in the UK, which is more than 160,000 deaths each year.5
The marketing authorization is also timely in the wake of the COVID-19 pandemic, which has resulted in the reprioritization of clinical resources, often leaving patients with serious cardiovascular disease to delay much needed medical help.6 Preventative care is needed for at-risk patients with cardiovascular disease, including LDL-cholesterol management and additional treatments for statin-treated patients with residual cardiovascular risk, identified by elevated triglycerides and other risk factors, to address their unmet need.
“Icosapent ethyl has been helping to reduce strokes, heart attacks and other major cardiovascular events in high-risk patients in the United States,” stated John Thero, president and chief executive officer of Amarin. “We are dedicated to the rethinking of cardiovascular disease risk reduction across Europe with an emphasis on preventative care. Amarin will work tirelessly throughout Europe to make icosapent ethyl available to all patients who may benefit from this important therapy.”
In addition, the company announced that subsequent to the marketing authorization by the EC, the Norwegian Medicines Agency informed Amarin of its marketing authorization for VAZKEPA in Norway.
Information regarding Amarin’s plans for commercialization and securing market access in Europe and the United Kingdom can be found in the FAQ section under investor relations at www.amarincorp.com.
About Amarin
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our scientific research foundation to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, and Zug in Switzerland as well as commercial partners and suppliers around the world. We are committed to rethinking cardiovascular risk through the advancement of scientific understanding of the impact on society of significant residual risk that exists beyond traditional therapies, such as statins for cholesterol management.
Wenigstens Steve Cohen glaubt an Amarin:
Billionaire Steve Cohen’s Top 10 Small-Cap Stock Picks
Ruchi Gupta
Wed, April 21, 2021, 7:18 PM
In this article we presented billionaire Steve Cohen's top 10 small-cap stock picks. You can skip our detailed discussion on Cohen's investment philosophy and read Billionaire Steve Cohen's Top 5 Small-Cap Stock Picks.
Steve A. Cohen is the owner of Point72 Asset Management, one of the most successful hedge funds in the U.S. He started off his Wall Street career as a junior trader at Gruntal & Co., where he dealt with options arbitrage. Cohen started his first hedge fund known as S.A.C. Capital Advisors in 1992, enjoying some success which allowed him to own 8 percent of Major League Baseball team, the New York Mets. He has also been involved in philanthropic causes in which he contributed $715 million.
Unfortunately, SAC Capital was allegedly involved in an insider trading scandal which led to a hefty $1.8 billion fine, and Cohen had to shut down the fund. This pave the way for the birth of his current hedge fund.
Point72 Asset Management
This is Cohen’s current hedge fund, based in Stamford. It has 17 clients, and its core strategy is long/short equity with investments in various asset classes across the globe. It has a particular focus on systematic, long/short, macro, and discretionary long/short strategies. The hedge fund attributes its success to the following:
Macro insights and highlights
Sector-aligned model
Multi-manager platform
A fundamental bottom-up research culture
Focus on multiple asset classes
Portfolio percentage
The fund has 10.5% of its portfolio invested in communications industry, 21.8% in healthcare was, 18.9% in information technology, 14.48% in consumer discretionary, and 14.74% in finance.
Point72 Asset Management’s performance highlights
The hedge fund’s market value in Q4 2020 was $20.5 billion, a notable improvement from the Q3 2020 market value of $19.53 billion. The performance in the last four quarters was up 35.28%. In comparison, the hedge fund gave a return of 14.9% net of fees in 2019. Point72 Asset Management added 357 new stocks to its portfolio and purchased additional shares in 216 stocks. The hedge fund also reported that 376 stocks were sold out. It also reduced its holdings in 287 stocks.
Some of the stocks at the top of Point72 Asset Management’s portfolio include Alphabet Inc. (NASDAQ: GOOG), Advanced Micro Devices, Inc. (NASDAQ: AMD), SPDR S&P 500 ETF Trust (NYSE: SPY), Facebook, Inc. (NASDAQ: FB), Visa Inc. (NYSE: V), Microsoft Corporation (NASDAQ: MSFT), AstraZeneca PLC (NASDAQ: AZN), Uber Technologies, Inc. (NYSE: UBER), Dell Technologies Inc. (NYSE: DELL), and SPDR S&P Biotech ETF (NYSE: XBI).
Cohen is an exception in an industry that is reeling from losses. The entire hedge fund industry is feeling the reverberations of the changing financial landscape. Its reputation has been tarnished in the last decade, during which its hedged returns couldn’t keep up with the unhedged returns of the market indices. On the other hand, Insider Monkey’s research was able to identify in advance a select group of hedge fund holdings that outperformed the S&P 500 ETFs by more than 124 percentage points since March 2017. Between March 2017 and February 26th 2021 our monthly newsletter’s stock picks returned 197.2%, vs. 72.4% for the SPY. Our stock picks outperformed the market by more than 124 percentage points (see the details here). We were also able to identify in advance a select group of hedge fund holdings that significantly underperformed the market. We have been tracking and sharing the list of these stocks since February 2017 and they lost 13% through November 16th. That’s why we believe hedge fund sentiment is an extremely useful indicator that investors should pay attention to. You can subscribe to our free newsletter on our homepage to receive our stories in your inbox.
Billionaire Steve Cohen's Top 10 Small-Cap Stock Picks
Billionaire Steve Cohen's Top 10 Small-Cap Stock Picks
Let's take a look at Steve Cohen's top 10 small-cap stock picks by analyzing his Q4'2020 portfolio.
Best Small-Cap Stocks to Buy According to Billionaire Steve Cohen
10. At Home Group Inc. (NYSE: HOME)
Number of Hedge Fund Holders: 31
At Home Group owns home décor stores that sell wall décor, home furniture, furnishings, houseware, rugs, and decorative accents. At Home Group sells its products across the U.S. CAS Investment Partners was the largest hedge fund investor with 10.4 million shares.
At Home Group reported a $1.08 non-GAAP EPS in Q4 2020, which was $0.38 more than the consensus estimate. Its GAAP EPS was $1.08, which was higher than the consensus estimates by $0.44.
The company's revenue for the quarter was $561.99 million, which outperformed the consensus estimate by $36.18 million and represented a 41.3% gain YOY.
At Home Group's adjusted EBITDA in Q4 2020 was $119.6 million, representing a 94.4% increase.
As of the end of the fourth quarter, 31 hedge funds in Insider Monkey’s database of 887 funds held stakes in HOME, compared to 34 funds in the third quarter. Clifford A. Sosin's CAS Investment Partners is the biggest stakeholder in the company, with 10.4 million shares, worth $161.3 million.
Bonhoeffer Capital Management, in their Q4 2020 investor letter, said that At Home Group Inc. (NYSE: HOME)’s current opportunity for organic growth is high. Here is what Bonhoeffer Capital Management has to say about At Home Group Inc. in their Q4 2020 investor letter:
"At Home (HOME) is a home décor retailer. At Home provides home accessories (rugs, housewares, furniture, wall hangings, etc.) in a self-service format similar to Costco. The company has 219 stores in 40 states across the United States. The average size of an At Home store is 105,000 square feet offering over 50,000 SKUs. This is larger than other home décor retailer whose average store size is about 25,000 square feet. They also lease second-generation real estate resulting in a lower lease cost (average $6/ft2) than competitors. In Rochester, At Home is an old grocery location (the number two grocer in Rochester) which they have upgraded to remove the “grungy” grocer appearance.
The company’s value proposition is to provide a wide selection of goods at a low price point ($15 per item and less than $70 per basket). The stores have limited staff to support the self-service environment. In visits to local stores, At Home focuses on areas like carpets, barstools/seats, and wall decor of which other retailers have limited selections. Over 70% of the At Home merchandise is exclusive to At Home; so At Home can make both the retail and branded product margins for these products.
At Home is not the largest competitor in the home décor market. Much of home décor is sold by generalists such as Walmart, Target, Home Depot, Amazon, and Lowe’s. These firms have 35% of the home décor market. At Home is a home décor specialty store like HomeGoods (owned by TJ Maxx), Williams Sonoma, and Bed Bath & Beyond. The market is quite competitive and players who have not been able to generate profitability have gone bankrupt, including Pier 1, with 1,500 stores nationwide. At Home has also pivoted to provide “buy online, pick up in store” (BOPIS) during COVID to ensure sales continue despite the pandemic.
Why Do Customers Keep Coming Back?
Retailers who do not have recurring revenue can create recurring revenue by ensuring customers have a reason to return to the store or website. This brings to mind a local store in Rochester, Wegmans, that makes the shopping experience pleasurable and provides a wide selection of grocery items. The wide selection brings folks in, and the experience keeps them coming back. [read complete letter here]
9. Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH)
Number of Hedge Fund Holders: 24
This is a biopharma that develops immunosuppressive treatments. The stock jumped earlier this year after the company received FDA approval for LUPKYNIS (voclosporin) for adults with active lupus nephritis, a rare disease that affects about a third of people diagnosed with systemic lupus erythematosus. Investment firm Cantor Fitzgerald expects the treatment to deliver over $00 million in sales for the company.
Healthcor Management LP currently owns 6.9 million shares of AUPH, worth $95.9 million. AUPH occupies 3.7% of Healthcor’s overall equity.
8. Boot Barn Holdings, Inc. (NYSE: BOOT)
Number of Hedge Fund Holders: 20
It is one of the leading retailers in the U.S, with a robust portfolio of products that include apparel, footwear, and accessories for adults and children regardless of gender. It offers both lifestyle and work-related products from numerous brands. Boot Barn has 266 stores distributed across 36 states and an e-commerce website called bootbarn.com.
Boot Barn Q3 2020 financials revealed that it underperformed its top and bottom lines.
It reported a gross profit of $106.8 million from the previous $97 million, while its margin increased from 34.2% to 35.3%.
Net sales were reported at $302.3 million, representing 6.5%. Same-store sales were up 4.6%, largely aided by the impressive 16.3% improvement in e-commerce sales, which overshadowed the meager 1.9% increase in same-store sales.
Boot Barn’s operating income was $41.6 million, representing a 19% gain while margin improved from 12.5% to 13.8% during the quarterly period. The company’s net income for the same period was $29.6 million, an improvement from the $24.8 million reported in the previous quarter.
The company had $76.3 million in cash and cash equivalents at the end of the quarter.
Boot Barn CEO, Jim Conroy acknowledged the 150-basis-point improvement in the company's operating margin, which he believes aligns with the growth observed in same-store sales.
Boot Barn's performance during its fiscal Q3 2020 validates its inclusion in Steve Cohen's top 10 small-cap stocks list.
Israel Englander's Millennium Management currently holds 519,273 shares of Boot Barn that amounts $22.5 million. BOOT occupies 0.01% of Millennium Management’s total portfolio. Boot Barn attracted 20 hedge fund investors in Q4 2020, which was higher than 13 hedge funds in Q3 2020.
7. Amarin Corporation plc (NASDAQ: AMRN)
Number of Hedge Fund Holders: 24
Amarin Corporation plc (NASDAQ: AMRN) is an Ireland-based company that develops and sells medicines for the treatment of cardiovascular disease. One of the products that the company offers is the drug Vascepa, a prescription grade omega-3 fatty acid that competes against similar drugs made by bigger biotech firms. Amarin sells the medicines it makes to wholesale dealers and pharmacy providers. It was founded in 1989 and is placed first on our list of 10 best biotech stocks under $6 in 2021.
The firm is in partnership with Mochida Pharmaceutical Co., Ltd. to develop and sell drug products based on Vascepa. The Irish firm posted an annual revenue of more than $600 million in December 2020. Amarin was previously known as Ethical Holdings plc but changed the name to Amarin Corporation plc in 1999. Out of the hedge funds being tracked by Insider Monkey, New York-based Baker Bros. Advisors hold the most shares in the firm – 27.9 million – worth more than $136 million. Eversept Partners was second with shares worth $78 million.
6. Knowles Corporation (NYSE: KN)
Number of Hedge Fund Holders: 27
It is one of the leading global players in the manufacture of precision device solutions and advanced micro-acoustic audio processing. Some of its markets include the communications, consumer mobile, automotive, defense, medtech, and industrial segments. The company leverages its advantageous position in advanced audio processing and MEMS (micro-electro-mechanical systems) microphones to enhance user experience in IoT, ear, and mobile applications.
Knowles Corp is also one of the leading authorities in mmWave RF, high-end capacitors, and acoustic components. This makes it a key player in supplying important components for technologies such as 5G, strategic for growth.
Knowles reported a $0.41 non-GAAP EPS in Q4 2020, outperforming the consensus EPS estimate by $0.04. Its GAAP EPS for the same period was $0.32, outperforming the estimate by $0.02.
The company's revenue for the quarterly period was $243.2 million, representing a 4.0% gain year-over-year.
As of the end of the fourth quarter of 2020, John W. Rogers' Ariel Investments owns 4.6 million shares of Knowles Corp. worth $85.7 million. KN accounts for 0.96% of Ariel Investments' total portfolio. There were 27 hedge funds that realized KN's potential and invested in the company in the fourth quarter of 2020.
Billionaire Steve Cohen’s Top 10 Small-Cap Stock Picks
Ruchi Gupta
Wed, April 21, 2021, 7:18 PM
In this article we presented billionaire Steve Cohen's top 10 small-cap stock picks. You can skip our detailed discussion on Cohen's investment philosophy and read Billionaire Steve Cohen's Top 5 Small-Cap Stock Picks.
Steve A. Cohen is the owner of Point72 Asset Management, one of the most successful hedge funds in the U.S. He started off his Wall Street career as a junior trader at Gruntal & Co., where he dealt with options arbitrage. Cohen started his first hedge fund known as S.A.C. Capital Advisors in 1992, enjoying some success which allowed him to own 8 percent of Major League Baseball team, the New York Mets. He has also been involved in philanthropic causes in which he contributed $715 million.
Unfortunately, SAC Capital was allegedly involved in an insider trading scandal which led to a hefty $1.8 billion fine, and Cohen had to shut down the fund. This pave the way for the birth of his current hedge fund.
Point72 Asset Management
This is Cohen’s current hedge fund, based in Stamford. It has 17 clients, and its core strategy is long/short equity with investments in various asset classes across the globe. It has a particular focus on systematic, long/short, macro, and discretionary long/short strategies. The hedge fund attributes its success to the following:
Macro insights and highlights
Sector-aligned model
Multi-manager platform
A fundamental bottom-up research culture
Focus on multiple asset classes
Portfolio percentage
The fund has 10.5% of its portfolio invested in communications industry, 21.8% in healthcare was, 18.9% in information technology, 14.48% in consumer discretionary, and 14.74% in finance.
Point72 Asset Management’s performance highlights
The hedge fund’s market value in Q4 2020 was $20.5 billion, a notable improvement from the Q3 2020 market value of $19.53 billion. The performance in the last four quarters was up 35.28%. In comparison, the hedge fund gave a return of 14.9% net of fees in 2019. Point72 Asset Management added 357 new stocks to its portfolio and purchased additional shares in 216 stocks. The hedge fund also reported that 376 stocks were sold out. It also reduced its holdings in 287 stocks.
Some of the stocks at the top of Point72 Asset Management’s portfolio include Alphabet Inc. (NASDAQ: GOOG), Advanced Micro Devices, Inc. (NASDAQ: AMD), SPDR S&P 500 ETF Trust (NYSE: SPY), Facebook, Inc. (NASDAQ: FB), Visa Inc. (NYSE: V), Microsoft Corporation (NASDAQ: MSFT), AstraZeneca PLC (NASDAQ: AZN), Uber Technologies, Inc. (NYSE: UBER), Dell Technologies Inc. (NYSE: DELL), and SPDR S&P Biotech ETF (NYSE: XBI).
Cohen is an exception in an industry that is reeling from losses. The entire hedge fund industry is feeling the reverberations of the changing financial landscape. Its reputation has been tarnished in the last decade, during which its hedged returns couldn’t keep up with the unhedged returns of the market indices. On the other hand, Insider Monkey’s research was able to identify in advance a select group of hedge fund holdings that outperformed the S&P 500 ETFs by more than 124 percentage points since March 2017. Between March 2017 and February 26th 2021 our monthly newsletter’s stock picks returned 197.2%, vs. 72.4% for the SPY. Our stock picks outperformed the market by more than 124 percentage points (see the details here). We were also able to identify in advance a select group of hedge fund holdings that significantly underperformed the market. We have been tracking and sharing the list of these stocks since February 2017 and they lost 13% through November 16th. That’s why we believe hedge fund sentiment is an extremely useful indicator that investors should pay attention to. You can subscribe to our free newsletter on our homepage to receive our stories in your inbox.
Billionaire Steve Cohen's Top 10 Small-Cap Stock Picks
Billionaire Steve Cohen's Top 10 Small-Cap Stock Picks
Let's take a look at Steve Cohen's top 10 small-cap stock picks by analyzing his Q4'2020 portfolio.
Best Small-Cap Stocks to Buy According to Billionaire Steve Cohen
10. At Home Group Inc. (NYSE: HOME)
Number of Hedge Fund Holders: 31
At Home Group owns home décor stores that sell wall décor, home furniture, furnishings, houseware, rugs, and decorative accents. At Home Group sells its products across the U.S. CAS Investment Partners was the largest hedge fund investor with 10.4 million shares.
At Home Group reported a $1.08 non-GAAP EPS in Q4 2020, which was $0.38 more than the consensus estimate. Its GAAP EPS was $1.08, which was higher than the consensus estimates by $0.44.
The company's revenue for the quarter was $561.99 million, which outperformed the consensus estimate by $36.18 million and represented a 41.3% gain YOY.
At Home Group's adjusted EBITDA in Q4 2020 was $119.6 million, representing a 94.4% increase.
As of the end of the fourth quarter, 31 hedge funds in Insider Monkey’s database of 887 funds held stakes in HOME, compared to 34 funds in the third quarter. Clifford A. Sosin's CAS Investment Partners is the biggest stakeholder in the company, with 10.4 million shares, worth $161.3 million.
Bonhoeffer Capital Management, in their Q4 2020 investor letter, said that At Home Group Inc. (NYSE: HOME)’s current opportunity for organic growth is high. Here is what Bonhoeffer Capital Management has to say about At Home Group Inc. in their Q4 2020 investor letter:
"At Home (HOME) is a home décor retailer. At Home provides home accessories (rugs, housewares, furniture, wall hangings, etc.) in a self-service format similar to Costco. The company has 219 stores in 40 states across the United States. The average size of an At Home store is 105,000 square feet offering over 50,000 SKUs. This is larger than other home décor retailer whose average store size is about 25,000 square feet. They also lease second-generation real estate resulting in a lower lease cost (average $6/ft2) than competitors. In Rochester, At Home is an old grocery location (the number two grocer in Rochester) which they have upgraded to remove the “grungy” grocer appearance.
The company’s value proposition is to provide a wide selection of goods at a low price point ($15 per item and less than $70 per basket). The stores have limited staff to support the self-service environment. In visits to local stores, At Home focuses on areas like carpets, barstools/seats, and wall decor of which other retailers have limited selections. Over 70% of the At Home merchandise is exclusive to At Home; so At Home can make both the retail and branded product margins for these products.
At Home is not the largest competitor in the home décor market. Much of home décor is sold by generalists such as Walmart, Target, Home Depot, Amazon, and Lowe’s. These firms have 35% of the home décor market. At Home is a home décor specialty store like HomeGoods (owned by TJ Maxx), Williams Sonoma, and Bed Bath & Beyond. The market is quite competitive and players who have not been able to generate profitability have gone bankrupt, including Pier 1, with 1,500 stores nationwide. At Home has also pivoted to provide “buy online, pick up in store” (BOPIS) during COVID to ensure sales continue despite the pandemic.
Why Do Customers Keep Coming Back?
Retailers who do not have recurring revenue can create recurring revenue by ensuring customers have a reason to return to the store or website. This brings to mind a local store in Rochester, Wegmans, that makes the shopping experience pleasurable and provides a wide selection of grocery items. The wide selection brings folks in, and the experience keeps them coming back. [read complete letter here]
9. Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH)
Number of Hedge Fund Holders: 24
This is a biopharma that develops immunosuppressive treatments. The stock jumped earlier this year after the company received FDA approval for LUPKYNIS (voclosporin) for adults with active lupus nephritis, a rare disease that affects about a third of people diagnosed with systemic lupus erythematosus. Investment firm Cantor Fitzgerald expects the treatment to deliver over $00 million in sales for the company.
Healthcor Management LP currently owns 6.9 million shares of AUPH, worth $95.9 million. AUPH occupies 3.7% of Healthcor’s overall equity.
8. Boot Barn Holdings, Inc. (NYSE: BOOT)
Number of Hedge Fund Holders: 20
It is one of the leading retailers in the U.S, with a robust portfolio of products that include apparel, footwear, and accessories for adults and children regardless of gender. It offers both lifestyle and work-related products from numerous brands. Boot Barn has 266 stores distributed across 36 states and an e-commerce website called bootbarn.com.
Boot Barn Q3 2020 financials revealed that it underperformed its top and bottom lines.
It reported a gross profit of $106.8 million from the previous $97 million, while its margin increased from 34.2% to 35.3%.
Net sales were reported at $302.3 million, representing 6.5%. Same-store sales were up 4.6%, largely aided by the impressive 16.3% improvement in e-commerce sales, which overshadowed the meager 1.9% increase in same-store sales.
Boot Barn’s operating income was $41.6 million, representing a 19% gain while margin improved from 12.5% to 13.8% during the quarterly period. The company’s net income for the same period was $29.6 million, an improvement from the $24.8 million reported in the previous quarter.
The company had $76.3 million in cash and cash equivalents at the end of the quarter.
Boot Barn CEO, Jim Conroy acknowledged the 150-basis-point improvement in the company's operating margin, which he believes aligns with the growth observed in same-store sales.
Boot Barn's performance during its fiscal Q3 2020 validates its inclusion in Steve Cohen's top 10 small-cap stocks list.
Israel Englander's Millennium Management currently holds 519,273 shares of Boot Barn that amounts $22.5 million. BOOT occupies 0.01% of Millennium Management’s total portfolio. Boot Barn attracted 20 hedge fund investors in Q4 2020, which was higher than 13 hedge funds in Q3 2020.
7. Amarin Corporation plc (NASDAQ: AMRN)
Number of Hedge Fund Holders: 24
Amarin Corporation plc (NASDAQ: AMRN) is an Ireland-based company that develops and sells medicines for the treatment of cardiovascular disease. One of the products that the company offers is the drug Vascepa, a prescription grade omega-3 fatty acid that competes against similar drugs made by bigger biotech firms. Amarin sells the medicines it makes to wholesale dealers and pharmacy providers. It was founded in 1989 and is placed first on our list of 10 best biotech stocks under $6 in 2021.
The firm is in partnership with Mochida Pharmaceutical Co., Ltd. to develop and sell drug products based on Vascepa. The Irish firm posted an annual revenue of more than $600 million in December 2020. Amarin was previously known as Ethical Holdings plc but changed the name to Amarin Corporation plc in 1999. Out of the hedge funds being tracked by Insider Monkey, New York-based Baker Bros. Advisors hold the most shares in the firm – 27.9 million – worth more than $136 million. Eversept Partners was second with shares worth $78 million.
6. Knowles Corporation (NYSE: KN)
Number of Hedge Fund Holders: 27
It is one of the leading global players in the manufacture of precision device solutions and advanced micro-acoustic audio processing. Some of its markets include the communications, consumer mobile, automotive, defense, medtech, and industrial segments. The company leverages its advantageous position in advanced audio processing and MEMS (micro-electro-mechanical systems) microphones to enhance user experience in IoT, ear, and mobile applications.
Knowles Corp is also one of the leading authorities in mmWave RF, high-end capacitors, and acoustic components. This makes it a key player in supplying important components for technologies such as 5G, strategic for growth.
Knowles reported a $0.41 non-GAAP EPS in Q4 2020, outperforming the consensus EPS estimate by $0.04. Its GAAP EPS for the same period was $0.32, outperforming the estimate by $0.02.
The company's revenue for the quarterly period was $243.2 million, representing a 4.0% gain year-over-year.
As of the end of the fourth quarter of 2020, John W. Rogers' Ariel Investments owns 4.6 million shares of Knowles Corp. worth $85.7 million. KN accounts for 0.96% of Ariel Investments' total portfolio. There were 27 hedge funds that realized KN's potential and invested in the company in the fourth quarter of 2020.
Trading Spotlight
Antwort auf Beitrag Nr.: 67.864.048 von bernie55 am 18.04.21 19:16:10Hier noch mal der Artikel vom 29.08.20 vom European Heart Journal mit dem Titel:
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy:
Final results of the EVAPORATE trial
LINK: https://academic.oup.com/eurheartj/article/41/40/3925/589883…
Change in Plaque Quantity Based on Treatmeng Group
.....und hier eine CT Aufnahme von der Low - Plaque Reduzierung.
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy:
Final results of the EVAPORATE trial
LINK: https://academic.oup.com/eurheartj/article/41/40/3925/589883…
Change in Plaque Quantity Based on Treatmeng Group
.....und hier eine CT Aufnahme von der Low - Plaque Reduzierung.
Antwort auf Beitrag Nr.: 67.857.704 von Magnetfeldfredy am 17.04.21 16:24:40INVESTOR RELATIONS
VASCEPA® (ICOSAPENT ETHYL) FOUND IN PRESPECIFIED AND POST HOC ANALYSES TO SIGNIFICANTLY REDUCE STROKE IN AT-RISK PATIENTS IN ANALYSES OF LANDMARK REDUCE-IT® STUDY PRESENTED AT INTERNATIONAL STROKE CONFERENCE 2021
https://investor.amarincorp.com/news-releases/news-release-d…
O.g. NEWS ist bereits am 29.08.20 veröffentlicht worden.
Bei dieser News ist die Plaque-Stabilisierung die NEUE Nachricht, von der am 29.08.20 noch nicht berichtet wurde.
Effect on coronary plaque stabilization reported to be significant at 9 months and sustained at 18 months
The EVAPORATE plaque morphology study provides valuable insight into how we can utilize scientific imaging to examine the mechanisms at work that may contribute to observed clinical trial results,” commented Matthew Budoff, M.D., Director of Cardiovascular CT at The Lundquist Institute and Professor of Medicine at the David Geffen School of Medicine at UCLA, the study sponsor. “The results suggest consistent benefits of icosapent ethyl on clinical cardiovascular outcomes as observed in the REDUCE-IT cardiovascular outcomes study, and on plaque progression and plaque vulnerability as observed in EVAPORATE.”
Die aktualisierten Daten bestätigen die Ergebnisse früherer Studien und es wird darauf hingewiesen, dass mehr/größere Studien gemacht werden müssen.
The primary limitation of this single coronary plaque study as identified by its investigators is its small sample size.
More study is needed to more fully understand the effects of VASCEPA on coronary plaque to determine the relationship, if any, of such plaque effects on cardiovascular risk reduction.
VASCEPA® (ICOSAPENT ETHYL) FOUND IN PRESPECIFIED AND POST HOC ANALYSES TO SIGNIFICANTLY REDUCE STROKE IN AT-RISK PATIENTS IN ANALYSES OF LANDMARK REDUCE-IT® STUDY PRESENTED AT INTERNATIONAL STROKE CONFERENCE 2021
https://investor.amarincorp.com/news-releases/news-release-d…
O.g. NEWS ist bereits am 29.08.20 veröffentlicht worden.
Bei dieser News ist die Plaque-Stabilisierung die NEUE Nachricht, von der am 29.08.20 noch nicht berichtet wurde.
Effect on coronary plaque stabilization reported to be significant at 9 months and sustained at 18 months
The EVAPORATE plaque morphology study provides valuable insight into how we can utilize scientific imaging to examine the mechanisms at work that may contribute to observed clinical trial results,” commented Matthew Budoff, M.D., Director of Cardiovascular CT at The Lundquist Institute and Professor of Medicine at the David Geffen School of Medicine at UCLA, the study sponsor. “The results suggest consistent benefits of icosapent ethyl on clinical cardiovascular outcomes as observed in the REDUCE-IT cardiovascular outcomes study, and on plaque progression and plaque vulnerability as observed in EVAPORATE.”
Die aktualisierten Daten bestätigen die Ergebnisse früherer Studien und es wird darauf hingewiesen, dass mehr/größere Studien gemacht werden müssen.
The primary limitation of this single coronary plaque study as identified by its investigators is its small sample size.
More study is needed to more fully understand the effects of VASCEPA on coronary plaque to determine the relationship, if any, of such plaque effects on cardiovascular risk reduction.
Antwort auf Beitrag Nr.: 67.857.704 von Magnetfeldfredy am 17.04.21 16:24:40Der Kurs wird reif geschossen für eine Übernahme
anders ist das eigentlich nicht mehr zu erklären
wenn wir uns jetzt auf 5$ festsetzen, sollte der Buyout gerne kommen für 50 $
anders ist das eigentlich nicht mehr zu erklären
wenn wir uns jetzt auf 5$ festsetzen, sollte der Buyout gerne kommen für 50 $
Geniale news zu unserer Wunderwaffe, Vascepa😍 gegen Herzinfarkt, Schlaganfall und Plaquereduktion in unseren Adern, unglaublch gut und unglaublich schlecht unser Aktienkurs:
VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Presented as Late-Breaking Science at ESC Preventive Cardiology 2021
Amarin Corporation plc
Sat, April 17, 2021, 3:50 PM·13 min read
Study quantified coronary plaque changes in patients administered 4 g/day of VASCEPA® (icosapent ethyl) on top of statin therapy
Effect on coronary plaque stabilization reported to be significant at 9 months and sustained at 18 months
DUBLIN, Ireland and BRIDGEWATER, N.J., April 17, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that further analyses from the Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides on Statin Therapy: EVAPORATE Trial were presented as Late-Breaking Science at European Society of Cardiology (ESC) Preventive Cardiology 2021, the Annual Congress of the European Association of Preventive Cardiology, on April 17, 2021, 3:50 PM CEST (Central European Summer Time) by Andrew Buckler, Founder and CTO of Elucid. As previously reported and published in the European Heart Journal, VASCEPA® (icosapent ethyl) demonstrated significant, 17% regression of low attenuation plaque (LAP) volume on multidetector computed tomography (MDCT) compared with placebo over 18 months. The Effect of Icosapent Ethyl on Changes in Coronary Plaque Morphology: EVAPORATE analyses presented at ESC Preventive Cardiology 2021 demonstrated that with administration of 4 g/day of VASCEPA on top of statin therapy, there was an observed change in plaque stability occurring at 9 months and sustained through 18 months.
“The EVAPORATE plaque morphology study provides valuable insight into how we can utilize scientific imaging to examine the mechanisms at work that may contribute to observed clinical trial results,” commented Matthew Budoff, M.D., Director of Cardiovascular CT at The Lundquist Institute and Professor of Medicine at the David Geffen School of Medicine at UCLA, the study sponsor. “The results suggest consistent benefits of icosapent ethyl on clinical cardiovascular outcomes as observed in the REDUCE-IT® cardiovascular outcomes study, and on plaque progression and plaque vulnerability as observed in EVAPORATE.”
Of the 80 patients that were enrolled in the randomized, double-blind, placebo-controlled EVAPORATE trial, 55 patients had images that were able to be utilized for the histology-validated software. The EVAPORATE plaque morphology study used ElucidVivo (Elucid, Boston, MA), the first FDA-cleared analysis for specific tissue characterization using histopathologic correlates to assess plaque morphology characteristics, including Lipid Rich Necrotic Core (LRNC), fibrous cap thickness, and intraplaque hemorrhage (IPH). Whereas with placebo LRNC increased and cap thickness decreased, both indicative of moving to a less stable phenotype, with icosapent ethyl there was a measured LRNC decrease and cap thickness increase, indicative of moving to a more stable phenotype.
“Coronary plaque stabilization is an important finding with VASCEPA and may explain, in part, the substantial cardiovascular benefit seen in REDUCE-IT,” said Craig Granowitz, M.D., Ph.D., Amarin’s senior vice president and chief medical officer. “The EVAPORATE plaque morphology study results provide additional insight into one of the likely multifactorial effects of VASCEPA, which effects collectively have been shown or observed to lower residual cardiovascular risk.”
The primary limitation of this single coronary plaque study as identified by its investigators is its small sample size. More study is needed to more fully understand the effects of VASCEPA on coronary plaque to determine the relationship, if any, of such plaque effects on cardiovascular risk reduction.
More information on ESC Preventive Cardiology 2021 can be found here.
About Amarin
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our scientific research foundation to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, and Zug in Switzerland as well as commercial partners and suppliers around the world. We are committed to rethinking cardiovascular risk through the advancement of scientific understanding of the impact on society of significant residual risk that exists beyond traditional therapies, such as statins for cholesterol management.
Unser neue CEO muss daraus einen Megablockbuster machen, alles andere wäre ein Witz, wie unser alter CEO, John Thero!
, unglaublch gut und unglaublich schlecht unser Aktienkurs:VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Presented as Late-Breaking Science at ESC Preventive Cardiology 2021
Amarin Corporation plc
Sat, April 17, 2021, 3:50 PM·13 min read
Study quantified coronary plaque changes in patients administered 4 g/day of VASCEPA® (icosapent ethyl) on top of statin therapy
Effect on coronary plaque stabilization reported to be significant at 9 months and sustained at 18 months
DUBLIN, Ireland and BRIDGEWATER, N.J., April 17, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that further analyses from the Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides on Statin Therapy: EVAPORATE Trial were presented as Late-Breaking Science at European Society of Cardiology (ESC) Preventive Cardiology 2021, the Annual Congress of the European Association of Preventive Cardiology, on April 17, 2021, 3:50 PM CEST (Central European Summer Time) by Andrew Buckler, Founder and CTO of Elucid. As previously reported and published in the European Heart Journal, VASCEPA® (icosapent ethyl) demonstrated significant, 17% regression of low attenuation plaque (LAP) volume on multidetector computed tomography (MDCT) compared with placebo over 18 months. The Effect of Icosapent Ethyl on Changes in Coronary Plaque Morphology: EVAPORATE analyses presented at ESC Preventive Cardiology 2021 demonstrated that with administration of 4 g/day of VASCEPA on top of statin therapy, there was an observed change in plaque stability occurring at 9 months and sustained through 18 months.
“The EVAPORATE plaque morphology study provides valuable insight into how we can utilize scientific imaging to examine the mechanisms at work that may contribute to observed clinical trial results,” commented Matthew Budoff, M.D., Director of Cardiovascular CT at The Lundquist Institute and Professor of Medicine at the David Geffen School of Medicine at UCLA, the study sponsor. “The results suggest consistent benefits of icosapent ethyl on clinical cardiovascular outcomes as observed in the REDUCE-IT® cardiovascular outcomes study, and on plaque progression and plaque vulnerability as observed in EVAPORATE.”
Of the 80 patients that were enrolled in the randomized, double-blind, placebo-controlled EVAPORATE trial, 55 patients had images that were able to be utilized for the histology-validated software. The EVAPORATE plaque morphology study used ElucidVivo (Elucid, Boston, MA), the first FDA-cleared analysis for specific tissue characterization using histopathologic correlates to assess plaque morphology characteristics, including Lipid Rich Necrotic Core (LRNC), fibrous cap thickness, and intraplaque hemorrhage (IPH). Whereas with placebo LRNC increased and cap thickness decreased, both indicative of moving to a less stable phenotype, with icosapent ethyl there was a measured LRNC decrease and cap thickness increase, indicative of moving to a more stable phenotype.
“Coronary plaque stabilization is an important finding with VASCEPA and may explain, in part, the substantial cardiovascular benefit seen in REDUCE-IT,” said Craig Granowitz, M.D., Ph.D., Amarin’s senior vice president and chief medical officer. “The EVAPORATE plaque morphology study results provide additional insight into one of the likely multifactorial effects of VASCEPA, which effects collectively have been shown or observed to lower residual cardiovascular risk.”
The primary limitation of this single coronary plaque study as identified by its investigators is its small sample size. More study is needed to more fully understand the effects of VASCEPA on coronary plaque to determine the relationship, if any, of such plaque effects on cardiovascular risk reduction.
More information on ESC Preventive Cardiology 2021 can be found here.
About Amarin
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our scientific research foundation to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, and Zug in Switzerland as well as commercial partners and suppliers around the world. We are committed to rethinking cardiovascular risk through the advancement of scientific understanding of the impact on society of significant residual risk that exists beyond traditional therapies, such as statins for cholesterol management.
Unser neue CEO muss daraus einen Megablockbuster machen, alles andere wäre ein Witz, wie unser alter CEO, John Thero!
Scripts solide, Generika schlecht, sehr gut:
JOHNNYTHEACE
48m
$AMRN as per Ihub
Vascepa
TRx 82,901; +0.7% w/w; +2.1% y/y
NRx 38,183; +1.4% w/w; +8.0% y/y
Ref 44,708; +0.1% w/w; -2.5% y/y
Generic Vascepa
TRx 7,739; -9.3% w/w; As % of total V: 8.1%
NRx 4,006; -11.0% w/w; As % of total V: 9.5%
Ref 3,332; -7.2% w/w; As % of total V: 6.9%
Lovaza (Generic & Brand)
TRx 60,827; -0.6% w/w; +1.3% y/y
NRx 30,115; -1.7% w/w; +9.8% y/y
Ref 30,712; +0.6% w/w; -5.8% y/y
8
JOHNNYTHEACE
48m
$AMRN as per Ihub
Vascepa
TRx 82,901; +0.7% w/w; +2.1% y/y
NRx 38,183; +1.4% w/w; +8.0% y/y
Ref 44,708; +0.1% w/w; -2.5% y/y
Generic Vascepa
TRx 7,739; -9.3% w/w; As % of total V: 8.1%
NRx 4,006; -11.0% w/w; As % of total V: 9.5%
Ref 3,332; -7.2% w/w; As % of total V: 6.9%
Lovaza (Generic & Brand)
TRx 60,827; -0.6% w/w; +1.3% y/y
NRx 30,115; -1.7% w/w; +9.8% y/y
Ref 30,712; +0.6% w/w; -5.8% y/y
8
Durchsuchen
Amarin - The Science Of Lipid Therapy
